Antimicrobial Resistance (AMR) is the ability of microbes — bacteria, viruses, fungi, parasites — to survive exposure to drugs that once killed them. AMR is a slow-moving pandemic. The Global Burden of AMR (Lancet, 2022) attributed 1.27 million deaths to bacterial AMR in 2019 and associated another 4.95 million. India carries one of the heaviest AMR burdens globally. For UPSC, AMR sits across GS Paper III (Science & Technology, Health) and GS Paper II (Governance, Social Justice).
What causes AMR?
Microbes evolve resistance via:
| Mechanism | Example |
|---|---|
| Enzymatic inactivation | Beta-lactamases break down penicillins |
| Target modification | Altered ribosomal RNA resists macrolides |
| Efflux pumps | Bacteria pump antibiotics out |
| Reduced permeability | Outer membrane changes block entry |
| Horizontal gene transfer | Plasmid-borne resistance spreads between species |
Drivers of AMR
| Driver | Contribution |
|---|---|
| Over-prescription in humans | Antibiotics given for viral flu, fever |
| OTC sale without prescription | Common in India despite H1 labelling |
| Under-dosing / incomplete courses | Encourages resistant survivors |
| Antibiotic use in livestock | Growth promoters; India's 2024 ban on colistin extended |
| Poultry and aquaculture | High fluoroquinolone use |
| Hospital-acquired infections (HAI) | ICUs breed multidrug-resistant organisms |
| Pharma effluents | Hyderabad, Vizag waterways with antibiotic residues |
| Poor sanitation & infection control | WASH and hospital hygiene gaps |
| International travel and trade | Global spread of resistance genes (NDM-1 discovered in Delhi) |
The Indian burden
- ~3 lakh newborn sepsis deaths annually (ICMR) — a significant share driven by AMR.
- ICMR AMR Surveillance Network (2013-ongoing) — shows resistance >70% in common bacteria like E. coli, Klebsiella to carbapenems in tertiary hospitals.
- India estimated 2.97 lakh AMR-attributable deaths (2019) — Lancet.
- Environmental AMR hotspots — Musi (Hyderabad), Yamuna, parts of coastal aquaculture belts.
Pathogens of concern — the "WHO priority list"
| Tier | Pathogens |
|---|---|
| Critical | Carbapenem-resistant Acinetobacter baumannii, P. aeruginosa, Enterobacteriaceae |
| High | Vancomycin-resistant Enterococcus faecium, MRSA, H. pylori, drug-resistant Salmonella |
| Medium | Penicillin-resistant Streptococcus pneumoniae, fluoroquinolone-resistant Shigella |
Fungal AMR has surged post-COVID — Candida auris and mucormycosis causing hospital outbreaks.
Global response
- WHO Global Action Plan on AMR (2015) — five objectives.
- UN Political Declaration on AMR (2016, reaffirmed Sept 2024) — pledges to cut AMR deaths.
- Tripartite-plus (WHO, FAO, WOAH, UNEP) — One Health platform.
- GLASS (Global Antimicrobial Resistance Surveillance System).
- AMR Multi-Partner Trust Fund and Fleming Fund for LMIC capacity.
- UNGA 2024 Political Declaration — target: 10% reduction in AMR-related deaths by 2030.
India's National Action Plan on AMR (NAP-AMR)
Released in 2017, aligned with WHO's Global Action Plan, with six strategic priorities:
| Priority | Actions |
|---|---|
| Awareness | Public campaigns, medical curriculum |
| Surveillance | AMR NAC (National AMR Surveillance Network) |
| Infection prevention | Hand hygiene, hospital antibiotic stewardship |
| Optimised antimicrobial use | Schedule H1, standard treatment guidelines |
| Research & innovation | ICMR consortia for new drugs, vaccines, diagnostics |
| Leadership & collaboration | Inter-ministerial coordination |
NAP-AMR 2.0 (2024-28) is being finalised with stronger One Health and quantitative targets.
Key regulations and initiatives
- Schedule H1 (2013) — H1 drugs can be sold only on prescription, records kept for 3 years.
- Red line on antibiotic packs (2016) — consumer cue not to self-medicate.
- FSSAI residue limits on antibiotics in milk, meat, poultry, seafood (2011; strengthened 2023).
- Ban on colistin in food animals (2019) — drug-of-last-resort; protected for human use.
- Kerala state AMR Strategic Action Plan (KARSAP) — India's first state-level plan.
- ICMR Indian Council of Medical Research AMR surveillance network across tertiary hospitals and 6 regional centres.
- NCDC AMR Surveillance Network for community infections.
The One Health approach
AMR cannot be solved in hospitals alone because resistance genes move between humans, animals and environment. One Health pulls in Ministry of Health, Ministry of Fisheries, Animal Husbandry & Dairying, Ministry of Environment, Ministry of Jal Shakti, and the pharma industry.
Key pillars:
- Rational use in human medicine.
- Ban on non-therapeutic antibiotic use in livestock and aquaculture.
- Vaccination of animals to reduce infection load.
- Sanitation (Swachh Bharat Mission) and safe water (Jal Jeevan Mission) to reduce infections at source.
- Pharma manufacturing effluent standards.
- Antimicrobial stewardship across sectors.
Innovation frontier
- Rapid diagnostics (RDx) — point-of-care molecular tests narrow empiric prescribing.
- Phage therapy — viruses that kill specific bacteria; revived interest.
- AI-driven antibiotic discovery — e.g., Halicin, Abaucin.
- Narrow-spectrum antibiotics — to avoid collateral resistance.
- Vaccines for resistant pathogens — Typhoid conjugate vaccine, Pneumococcal, Hib.
- CRISPR-based antimicrobials — targeting resistance genes.
- Microbiome restoration — faecal microbiota transplants for C. difficile.
Challenges
| Challenge | Detail |
|---|---|
| Pipeline drought | Few new antibiotic classes since 1987 |
| Low commercial incentive | Antibiotic stewardship limits sales |
| Diagnostic deficit | <5% of Indian labs do culture-sensitivity |
| Regulatory enforcement | H1 compliance uneven |
| Animal husbandry lobbying | Pushback against antibiotic bans |
| Data gaps in community | Most surveillance hospital-based |
| Awareness | Patients demand antibiotics for viral illness |
Latest developments (2024-26)
- UNGA Political Declaration on AMR (Sept 2024) — pledge to reduce AMR-attributable deaths by 10% by 2030; India is a signatory.
- India's NAP-AMR 2.0 (2024) — revised plan in consultations; tighter quantitative targets.
- Kerala declared India's first "AMR state" with integrated community stewardship.
- PM-ABHIM funds district-level labs for AMR surveillance.
- Launch of NARS-NET 2.0 — ICMR's expanded AMR network.
- ICMR-NMR Drug Development Programme — focusing on novel narrow-spectrum agents.
- AI Action Summit, Paris (Feb 2025) — AMR listed as priority AI-for-good use case.
- India Semiconductor Mission & DeepTech Policy 2024 — enabling biosensor and rapid diagnostic manufacture.
- National Quantum Mission (2024) — quantum biosensors for rapid infection detection.
- FSSAI veterinary drug residue mass-monitoring (2024-25).
- Chandrayaan-4 plan and Gaganyaan progress — space-grade microbiology insights feeding back into infection control research.
UPSC Relevance
GS Paper III — Science & Technology / Health
- Mechanisms, One Health, NAP-AMR.
GS Paper II — Governance
- Regulation of OTC sale, FSSAI, state capacity.
GS Paper II — Social Justice
- Access and affordability of newer antibiotics.
GS Paper IV — Ethics
- Prescribing ethics, pharma marketing.
Essay
- "The silent pandemic in our medicine cabinets."
Prelims pointers — Schedule H1, NDM-1, Red Line campaign, WHO Priority Pathogen List, NAP-AMR 2017, Kerala KARSAP, colistin ban 2019, One Health Tripartite-plus.
Interview probes — why pharma pipeline is dry; antibiotic stewardship in private sector; One Health coordination; AMR in aquaculture.
AMR is a slow pandemic whose casualties look individual but are systemic. India's demographic, pharmaceutical and agricultural scale make its leadership on AMR globally significant — and civically urgent.
Tell Google you want more of this.
Add Anantam IAS as a preferred sourceOne tap, and this site shows up more often in your own Top Stories, AI Overviews and AI Mode. Remove it any time.
